ArticleStroke (Hoboken, N.J.)2025
Mechanical Thrombectomy for Patients with Large Core Ischemic Strokes-An International Cost-Effectiveness Analysis.
Article in Stroke (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent trials demonstrate mechanical thrombectomy (MT) benefits patients with large core infarcts. This study assesses the cost-effectiveness of MT in this population across a range of international health care systems.
methodsA decision tree model coupled with a Markov model compared MT with medical management. Clinical outcomes, quality-adjusted life years, and costs were projected over a lifetime horizon. Data from recent randomized controlled trials and country-specific cost inputs informed the model. Univariate, bivariate deterministic, and probabilistic sensitivity analyses assessed parameter uncertainty.
resultsMT was consistently cost effective across all 11 health care systems, even though the magnitude of cost savings or added costs varied. Although MT resulted in net cost savings in Belgium, it was associated with increased costs in Australia and China; however, even in these systems, the added cost per quality-adjusted life year gained remained within acceptable thresholds. Incremental quality-adjusted life years gains were consistent across systems (1.16-1.98). Incremental cost-effectiveness ratios were below $20 000/quality-adjusted life years in all countries. Sensitivity analyses confirmed the robustness of these findings. Acute care costs for severely disabled patients (modified Rankin Scale score 4-6) most influenced cost-effectiveness.
conclusionOur study demonstrates the consistent value of mechanical thrombectomy for large core stroke patients across various health care settings, even with differences in costs between countries. This supports expanding mechanical thrombectomy access, which, although requiring investment, offers the potential for long-term cost-effectiveness through reduced disability and improved quality of life. It is important to note that this analysis adopts a health care system perspective, excluding indirect costs, and that assumptions regarding long-term outcomes may even potentially lead to an underestimation of the comprehensive cost-effectiveness of MT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.